Dotronix, Inc. has decided to engage in the rapidly growing industry of generating electricity through wind power for commercial sale to one or more power utilities.
Their initial wind farm most likely will be constructed in a rural farm location somewhere near the border of Minnesota and the Dakotas. Due to the substantial and significant differences between the wind power business and the business of developing and marketing OTC healthcare products, they have decided to separate the two businesses totally through a spinoff distribution of the common stock of their PuraMed BioScience subsidiary to all Dotronix shareholders on a pro rata basis. They anticipate the record date for this spinoff will be on or about January l5, 2007, and that its effective date will be within 30 days thereafter. After this spinoff stock distribution is completed, there will be no further direct operational or management connection between or common to the two companies.